摘要
目的分析二甲双胍辅助卡培他滨及奥沙利铂治疗结肠癌合并2型糖尿病患者的疗效及安全性。方法结直肠癌合并2型糖尿病患者58例,按治疗方案不同分为研究组(n=29)与参照组(n=29),参照组予以卡培他滨及奥沙利铂治疗,研究组在参照组基础上予以二甲双胍。对比两组疗效、不良反应发生率及治疗前后血糖[空腹血糖(FBG)、餐后2h血糖(2hPG)]。结果研究组总有效率62.07%较参照组31.03%高(P<0.05);治疗后,研究组FBG、2hPG水平较参照组低(P<0.05);研究组不良反应发生率17.24%较参照组41.38%低(P<0.05)。结论结直肠癌合并2型糖尿病患者予以二甲双胍辅助卡培他滨及奥沙利铂治疗效果显著,可降低患者血糖水平及不良反应发生率。
Objective To analyze the efficacy and safety of metformin in adjuvant treatment with capecitabine and oxaliplatin in patients with colon cancer and type 2 diabetes.Methods 58 patients with colorectal cancer and type 2 diabetes mellitus were divided into study group(n=29)and reference group(n=29)according to different treatment options.The patients were treated with capecitabine and oxaliplatin,and the study group received metformin on the basis of the reference group.The efficacy of the two groups,the incidence of adverse reactions and blood glucose before and after treatment [fasting blood glucose(FBG),postprandial 2h blood glucose(2hPG)] were compared.Results The total effective rate of the study group was 62.07%(18/29)higher than that of the reference group(31.03%(9/29)).After treatment,the FBG and 2hPG levels in the study group were lower than those in the reference group(P<0.05).The incidence of adverse reactions in the group was 17.24%(5/29),which was lower than that in the reference group(41.38%(12/29))(P<0.05).Conclusion Patients with colorectal cancer and type 2 diabetes have significant effects on metformin-assisted capecitabine and oxaliplatin,which can reduce the blood glucose level and the incidence of adverse reactions.
作者
刘北彦
李林
Liu Beiyan;Li Lin(Department of Endocrinology,The First Affiliated Hospital of Henan Xinxiang Medical College,Xinxiang453100,China;Department of Neurology,The First Affiliated Hospital of Henan Xinxiang Medical College,Xinxiang453100,China)
出处
《哈尔滨医药》
2020年第6期511-512,共2页
Harbin Medical Journal
